Learning Multiparametric Biomarkers for Assessing MR-Guided Focused Ultrasound Treatment of Malignant Tumors

  title={Learning Multiparametric Biomarkers for Assessing MR-Guided Focused Ultrasound Treatment of Malignant Tumors},
  author={Blake E. Zimmerman and Sara L Johnson and Henrik Od{\'e}en and Jill Shea and Markus Foote and Nicole S. Winkler and Sarang C. Joshi and Allison Payne},
  journal={IEEE Transactions on Biomedical Engineering},
Noninvasive MR-guided focused ultrasound (MRgFUS) treatments are promising alternatives to the surgical removal of malignant tumors. A significant challenge is assessing the viability of treated tissue during and immediately after MRgFUS procedures. Current clinical assessment uses the nonperfused volume (NPV) biomarker immediately after treatment from contrast-enhanced MRI. The NPV has variable accuracy, and the use of contrast agent prevents continuing MRgFUS treatment if tumor coverage is… 
1 Citations

Histology to 3D in vivo MR registration for volumetric evaluation of MRgFUS treatment assessment biomarkers

A novel MR to histology registration workflow that utilizes intermediate imaging and does not rely on anatomical features independent from treatment features to perform direct registration, and will facilitate validating novel MRgFUS biomarkers to improve treatment assessment without surgical intervention.



Multiparametric MRI Analysis for the Identification of High Intensity Focused Ultrasound-Treated Tumor Tissue

It is demonstrated that non-viable, HIFU-treated tumor tissue can be distinguished from viable, non- treated tumor tissue using multiparametric MRI analysis and may allow for automated, accurate and objective evaluation of HifU treatment.

MRI methods for the evaluation of high intensity focused ultrasound tumor treatment: Current status and future needs

The major acute and delayed effects of HIFU treatment are described and the MRI methods that have been—or could be—used to detect the associated tissue changes are described.

Prostate focused ultrasound focal therapy—imaging for the future

This Perspectives article will assess whether the current methods for cancer diagnosis, tissue targeting, and treatment follow up are accurate enough to allow the design of robust HIFU focal therapy protocols.

MR imaging of prostate after treatment with high-intensity focused ultrasound.

MR imaging results of the prostate show a consistent sequence of changes after treatment with HIFU and can provide information to the operator about completeness of treatment.

Dynamic contrast-enhanced magnetic resonance imaging for localization of recurrent prostate cancer after external beam radiotherapy.

MR-Guided High-Intensity Focused Ultrasound Ablation of Breast Cancer with a Dedicated Breast Platform

A novel and dedicated MR-HIFU breast platform has been designed for safe and effective MR- HIFU ablation of breast cancer and both clinical and technical challenges have to be solved before it can be implemented in routine clinical practice.

Evolution of the Ablation Region After Magnetic Resonance–Guided High-Intensity Focused Ultrasound Ablation in a Vx2 Tumor Model

The results indicate that CE-T1-w imaging is reliable for MR-HIFU treatment evaluation after 1 week, which underestimates the extent of tissue necrosis on histology in the initial few days, but after 1week, the NPA is reliable in delineating the necrotic tissue area.

A nonrigid registration algorithm for longitudinal breast MR images and the analysis of breast tumor response.

High-intensity focused ultrasound ablation of liver tumours: can radiological assessment predict the histological response?

It is demonstrated that HIFU is capable of achieving selective ablation of pre-defined regions of liver tumour targets, and that MRI evidence of complete ablationOf the target region can be taken to infer histological success.

Palliative treatment of painful bone metastases with MR imaging--guided focused ultrasound.

MR imaging-guided focused ultrasound is a noninvasive technique that allows palliative treatment of bone metastases with little or no morbidity.